{"id":"NCT02096705","sponsor":"AstraZeneca","briefTitle":"Phase III Insulin Add-On Asia Regional Program - ST","officialTitle":"A 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate Efficacy and Safety of Dapagliflozin Added to Therapy of Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-31","primaryCompletion":"2016-01-28","completion":"2016-01-28","firstPosted":"2014-03-26","resultsPosted":"2017-03-06","lastUpdate":"2017-08-09"},"enrollment":477,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Dapagliflozin Placebo","otherNames":[]}],"arms":[{"label":"Group 1: Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Group 2: Dapagliflozin Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Adjusted Mean Change in HbA1c From Baseline to Week 24","timeFrame":"Baseline (Day 1) and 24 weeks","effectByArm":[{"arm":"Placebo","deltaMin":0.03,"sd":0.0707},{"arm":"Dapagliflozin","deltaMin":-0.87,"sd":0.0666}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":29,"countries":["China","Singapore","South Korea"]},"refs":{"pmids":["38770818"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":139},"commonTop":["HYPERLIPIDAEMIA","HYPERURICAEMIA","DYSLIPIDAEMIA","UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS"]}}